Insmed Incorporated (NASDAQ:INSM) Shares Purchased by Captrust Financial Advisors

Captrust Financial Advisors boosted its holdings in Insmed Incorporated (NASDAQ:INSM) by 40.9% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 6,280 shares of the biopharmaceutical company’s stock after buying an additional 1,824 shares during the period. Captrust Financial Advisors’ holdings in Insmed were worth $458,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the business. Vestal Point Capital LP boosted its position in shares of Insmed by 113.3% in the third quarter. Vestal Point Capital LP now owns 1,600,000 shares of the biopharmaceutical company’s stock worth $116,800,000 after acquiring an additional 850,000 shares during the last quarter. Ally Bridge Group NY LLC boosted its holdings in shares of Insmed by 16.9% in the 3rd quarter. Ally Bridge Group NY LLC now owns 150,833 shares of the biopharmaceutical company’s stock valued at $11,011,000 after purchasing an additional 21,833 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Insmed by 7.3% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 36,721 shares of the biopharmaceutical company’s stock valued at $2,681,000 after purchasing an additional 2,485 shares during the last quarter. Acuta Capital Partners LLC boosted its holdings in Insmed by 49.1% in the third quarter. Acuta Capital Partners LLC now owns 107,500 shares of the biopharmaceutical company’s stock valued at $7,848,000 after acquiring an additional 35,400 shares during the last quarter. Finally, Blueshift Asset Management LLC acquired a new position in Insmed in the third quarter valued at $365,000.

Insider Buying and Selling at Insmed

In related news, insider Martina M.D. Flammer sold 13,436 shares of the stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $74.92, for a total transaction of $1,006,625.12. Following the sale, the insider now owns 106,134 shares in the company, valued at $7,951,559.28. This represents a 11.24 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 4.60% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the company. Bank of America lifted their target price on Insmed from $84.00 to $86.00 and gave the company a “buy” rating in a report on Wednesday, October 9th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Insmed in a research report on Monday, September 9th. JPMorgan Chase & Co. lifted their price target on shares of Insmed from $74.00 to $83.00 and gave the company an “overweight” rating in a research report on Friday, November 22nd. HC Wainwright restated a “buy” rating and set a $90.00 target price on shares of Insmed in a report on Friday, November 1st. Finally, Truist Financial restated a “buy” rating and set a $105.00 target price (up previously from $100.00) on shares of Insmed in a report on Friday, November 1st. One analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $83.67.

Insmed Trading Down 2.9 %

INSM opened at $72.05 on Friday. The stock has a market capitalization of $12.89 billion, a PE ratio of -12.98 and a beta of 1.10. The firm’s fifty day moving average price is $72.40 and its 200 day moving average price is $70.82. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. Insmed Incorporated has a 12-month low of $21.92 and a 12-month high of $80.53.

Insmed (NASDAQ:INSM) last issued its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.19) by ($0.08). The firm had revenue of $93.40 million for the quarter, compared to analyst estimates of $93.36 million. The business’s quarterly revenue was up 18.1% on a year-over-year basis. During the same quarter in the previous year, the business posted ($1.10) EPS. As a group, research analysts expect that Insmed Incorporated will post -5.44 EPS for the current fiscal year.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.